Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LXGTF moon walker ;)
Nice explanation tnx
Anither green day, no breaktrough yet but momo si around
Self-care medical device market is supposed to go to $16.9 billion by 2019.
https://www.prnewswire.com/news-releases/self-care-medical-devices-market-expected-to-reach-usd-169-billion-globally-in-2019-transparency-market-research-239009671.html
LXGTF announced receipt of the first HeartSentry human-use units from its manufacturer. http://techstockinsider.com/lexington-biosciences-lxgtf-receives-heartsentry-trial-units/
INDUSTRY WORTH BILLIONS HAVE YOU SAW IT, SOMEONE PUT A HAND ON IT TODAY!
http://techstockinsider.com/the-wearable-tech-thats-disrupting-an-industry-worth-billions/
LXGTF is potential 50 Billion Dollar Industry Penny Stock to Watch!
Read More here.
https://t.co/4nL5f2LtnQ
LXGTF engages Diablo research for next step in FDA clearance..
https://finance.yahoo.com/news/lexington-biosciences-engages-clinical-research-140000876.html
Lexington’s President Eric Willis comments, “After nine months of concerted effort by our design and production team, the arrival of our first human-use HeartSentry devices allows us to accelerate our plans to move ahead with our pilot study. Diablo Clinical Research is a proven and respected establishment with the capability to launch our research program efficiently and cost-effectively. They have been extremely helpful in the determination process which has led to today’s announcement. We are excited to begin this next step of our development phase, and look forward to sharing quantifiable results in the near future.
http://techstockinsider.com/lexington-biosciences-lxgtf-lnb-engages-clinical-research-organization/?utm_medium=Social&utm_source=TSI_Social_Link&utm_campaign=TSI_Social_1130
This thing is amazing!
WATCH for $LXGTF, big momo coming!
Watch for $LXGTF, big momo coming!!!!
Development Plan
• Develop regulatory plan and meet with FDA to confirm
• Create test platform for algorithm development
• Establish scientific advisory board
• Create quality system
• Identify and sign contract with manufacturing partner
• Manufacture units
• Acute calibration study
• Clinical study comparing cFMD to uFMD (or
other standard) and show positive correlation
• Submit for FDA approval with calibration study data
TEAM: AMAZING LEADERSHIP
The principals, directors and advisors of Lexington
BioSciences have been individually and collectively
involved in raising extensive capital funding for their
private and public companies. Team members have held
numerous executive leadership positions encompassing
biotechnology, and medical device companies, as well as
multi-national corporations. The team includes inventors,
scientists, and business people who have successfully
started, built and grown multiple life science companies.
OPPORTUNITY: HIGH GROWTH SELF-MONITORING SECTOR
By 2020, $2.6 billion Global monitoring instruments market
will increasingly shift to the high-growth home segment.
HeartSentryâ„¢ has been developed to measure the
function of the endothelium, the cells that line all
arteries and are critical to the prevention of
atherosclerosis, heart attacks and stroke.
HeartSentry targets the rapidly growing selfmeasurement
medical device sector and is designed
for both personal and clinical use. Simplicity and
functionality are key elements of the design.
Designed to efficiently measure increases in arterial
volume which occur when the endothelial cells of the
artery are stimulated, and the muscles in the wall of
the artery relax. Initial studies demonstrated a strong
correlation to ultrasound results.
LXGTF SOLUTION: EARLY DETECTION
The only way to detect that arteries are vulnerable to
atherosclerosis is to assess endothelial function. This is a
test of the endothelial cells that line all the arteries in the body.
The endothelium is the single layer of cells that line various
organs and cavities, especially the heart, blood and lymphatic
vessels. These cells act as a shield, preventing plaque from
forming inside the artery wall, and produce substances that
stop blood clots from developing in the vessel.
Healthy endothelial cells release nitric oxide (NO), which
is responsible for most of the protective functions of these
cells in the artery.
In an at-risk individual, the endothelial cells do not
produce enough NO, or the NO produced is deactivated
by chemicals in the bloodstream before it can prevent
deposits from forming in the arterial wall.
PROBLEM: HEART DISEASE IS A KILLER No.1
Nearly 1 in 3 deaths in the USA are caused by heart
disease and stroke. Of the approximately 1.5 million
people suffering heart attacks annually in the U.S., more
than 250,000 will die within one hour of their incident.
Nearly 1/3 of the ~ 600,000 annual cardiovascular
disease deaths in the U.S. could be prevented through
changes in lifestyle habits. Unfortunately, for up to 50%
of these individuals, the FIRST SYMPTOM of coronary
artery disease is sudden cardiac death, or a heart attack.
-Source: World Health Organization / Center for Disease
Control (CDC) Atlanta,
SHORT INTRODUCTION LXGTF IS YOU ARE NEW!
Lexington BioSciences introduces HeartSentry, a simple,
yet revolutionary technology for personalized measurement
and monitoring of vascular health to detect the potential
for cardiovascular disease at its earliest stages. The
device measures the function of the endothelium, the cells
that line all arteries and are critical to the prevention of
atherosclerosis, heart attacks and stroke.
Green green day :)
Good morning ADAC!
Yes I want see the breaktrough finaly, love the green closurea but want more....see the 50s lol
Good morning Italian, good to see you ;)
yes is running in slow mode some weeks but firmly and strongly going to the new level of greatness!
Love your positivity
Me too :)
HeartSentry Technology rectifies this alarming situation:
Quote:
The First Sign of Cardiovascular Disease is Often an Unannounced Heart Attack!
• Current first line cardiovascular health
diagnostics are insensitive at measuring
heart disease development and
progression
• Specialized cardiovascular diagnostics
are highly invasive and expensive and
generally catch cardiovascular disease
AFTER it’s developed
...we need a simple way to proactively measure and monitor
cardiovascular system health BEFORE the development of heart disease
LXGTF simplify and save lifes! Current Standards are Complicated and Expensive
• Gold standard - ULTRASOUND
• Measurement directly views arterial diameter
changes
• Only at specialized diagnostic centers
• Requires trained ultrasonographer
• Expensive capital equipment needed
• Alternative method - ENDOPAT
• Measurement uses a fingertip blood oxygen
sensor and laptop computer.
• Only at specialized diagnostic centers
• Requires trained technician
Currently only used in specialized research centers by highly trained staff
STEP BEFORE OTHERS! Endothelial function measurement predicts when arteries are vulnerable to developing atherosclerosis
WHY LXGTF is better? Knowing the core health of the cardiovascular system is critical to preventing future heart attacks and strokes
• Monitoring cardiovascular health changes over time is key to prevention via lifestyle modification, physician care and ongoing monitoring.
• Traditional measures of blood pressure and cholesterol measurements are only partial indicators of cardiovascular health.
They chose really the best of the best
Come on...green +3,8% power hour!!!
It will be awesome!
Absolutely... no other known
Green baby, still need more volume here...
Thank you
Love green but lets see more, need some more valume here
What we can see today? Time for breaktrough?
Good morning LXGTF friends!
I am thinking the same
Exactly and now we have the opportunity